Literature DB >> 18220960

Influenza viruses: basic biology and potential drug targets.

Christopher F Basler1.   

Abstract

Influenza A and influenza B viruses are continuing causes of morbidity and mortality on an annual basis. Influenza A viruses have historically caused periodic pandemics in the human population, sometimes with devastating consequences, such as in 1918. Fears of a new pandemic have increased in recent years because of continuing outbreaks of highly pathogenic H5N1 avian influenza viruses in birds with occasional, but often lethal infection of humans. Despite their importance as human pathogens, the antiviral drugs approved to treat influenza virus infections are currently limited to two targets, the viral neuraminidase and the viral ion channel, M2. The use of the M2 inhibitors amantadine and rimantadine is further limited by the propensity of these drugs to select for drug resistant variants. However, the replication cycle of influenza viruses has been intensively studied and is receiving increased attention. New opportunities exist to develop novel antiviral strategies targeting these viruses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18220960     DOI: 10.2174/187152607783018745

Source DB:  PubMed          Journal:  Infect Disord Drug Targets        ISSN: 1871-5265


  13 in total

Review 1.  Drugs in development for influenza.

Authors:  David A Boltz; Jerry R Aldridge; Robert G Webster; Elena A Govorkova
Journal:  Drugs       Date:  2010-07-30       Impact factor: 9.546

Review 2.  Progress in identifying virulence determinants of the 1918 H1N1 and the Southeast Asian H5N1 influenza A viruses.

Authors:  Christopher F Basler; Patricia V Aguilar
Journal:  Antiviral Res       Date:  2008-05-23       Impact factor: 5.970

3.  Peroxisome proliferator-activated receptor and AMP-activated protein kinase agonists protect against lethal influenza virus challenge in mice.

Authors:  Carson E Moseley; Robert G Webster; Jerry R Aldridge
Journal:  Influenza Other Respir Viruses       Date:  2010-09       Impact factor: 4.380

4.  MicroRNA regulation of human protease genes essential for influenza virus replication.

Authors:  Victoria A Meliopoulos; Lauren E Andersen; Paula Brooks; Xiuzhen Yan; Abhijeet Bakre; J Keegan Coleman; S Mark Tompkins; Ralph A Tripp
Journal:  PLoS One       Date:  2012-05-14       Impact factor: 3.240

5.  Diisopropylamine dichloroacetate, a novel pyruvate dehydrogenase kinase 4 inhibitor, as a potential therapeutic agent for metabolic disorders and multiorgan failure in severe influenza.

Authors:  Kazuhiko Yamane; Irene L Indalao; Junji Chida; Yoshikazu Yamamoto; Masaaki Hanawa; Hiroshi Kido
Journal:  PLoS One       Date:  2014-05-27       Impact factor: 3.240

6.  Using mutagenesis to explore conserved residues in the RNA-binding groove of influenza A virus nucleoprotein for antiviral drug development.

Authors:  Chia-Lin Liu; Hui-Chen Hung; Shou-Chen Lo; Ching-Hui Chiang; I-Jung Chen; John T-A Hsu; Ming-Hon Hou
Journal:  Sci Rep       Date:  2016-02-26       Impact factor: 4.379

Review 7.  Novel insights into proteolytic cleavage of influenza virus hemagglutinin.

Authors:  Stephanie Bertram; Ilona Glowacka; Imke Steffen; Annika Kühl; Stefan Pöhlmann
Journal:  Rev Med Virol       Date:  2010-09       Impact factor: 6.989

8.  Trends in global warming and evolution of matrix protein 2 family from influenza A virus.

Authors:  Shao-Min Yan; Guang Wu
Journal:  Interdiscip Sci       Date:  2009-11-14       Impact factor: 2.233

9.  Evaluation of a Set of C9 N-acyl Neu5Ac2en Mimetics as Viral Sialidase Selective Inhibitors.

Authors:  Sadagopan Magesh; Nongluk Sriwilaijaroen; Setsuko Moriya; Hiromune Ando; Taeko Miyagi; Yasuo Suzuki; Hideharu Ishida; Makoto Kiso
Journal:  Int J Med Chem       Date:  2010-12-08

10.  Confronting an influenza pandemic with inexpensive generic agents: can it be done?

Authors:  David S Fedson
Journal:  Lancet Infect Dis       Date:  2008-04-15       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.